These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
385 related articles for article (PubMed ID: 21879778)
1. Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review. Jones SC; Sorbello A; Boucher RM Drug Saf; 2011 Oct; 34(10):839-47. PubMed ID: 21879778 [TBL] [Abstract][Full Text] [Related]
2. [Fluoroquinolone associated myasthenia gravis exacerbation: clinical analysis of 9 cases]. Wang SH; Xie YC; Jiang B; Zhang JY; Qu Y; Zhao Y; Li Y; Qiao SS; Xu CL Zhonghua Yi Xue Za Zhi; 2013 May; 93(17):1283-6. PubMed ID: 24029473 [TBL] [Abstract][Full Text] [Related]
4. Prulifloxacin as a trigger of myasthenia gravis. Rossi M; Lusini G; Biasella A; Mazzocchio R J Neurol Sci; 2009 May; 280(1-2):109-10. PubMed ID: 19232642 [TBL] [Abstract][Full Text] [Related]
5. Emergency Department Management of a Myasthenia Gravis Patient with Community-Acquired Pneumonia: Does Initial Antibiotic Choice Lead to Cure or Crisis? Van Berkel MA; Twilla JD; England BS J Emerg Med; 2016 Feb; 50(2):281-5. PubMed ID: 26472607 [TBL] [Abstract][Full Text] [Related]
6. Pharmacosafety of fluoroquinolone and macrolide antibiotics in the clinical care of patients with myasthenia gravis. Pham Nguyen TP; Leonard CE; Bird SJ; Willis AW; Hamedani AG Muscle Nerve; 2021 Aug; 64(2):156-162. PubMed ID: 33719062 [TBL] [Abstract][Full Text] [Related]
7. Glucose homeostasis abnormalities associated with use of gatifloxacin. Frothingham R Clin Infect Dis; 2005 Nov; 41(9):1269-76. PubMed ID: 16206101 [TBL] [Abstract][Full Text] [Related]
8. Suspected Fluoroquinolone-Induced Exacerbation of Myasthenia Gravis in Dogs. Guzman KMH; Harkin K J Am Anim Hosp Assoc; 2023 Sep; 59(5):249-254. PubMed ID: 37708471 [TBL] [Abstract][Full Text] [Related]
9. Fluoroquinolone-associated tendon-rupture: a summary of reports in the Food and Drug Administration's adverse event reporting system. Arabyat RM; Raisch DW; McKoy JM; Bennett CL Expert Opin Drug Saf; 2015; 14(11):1653-60. PubMed ID: 26393387 [TBL] [Abstract][Full Text] [Related]
10. Diplopia and fluoroquinolones. Fraunfelder FW; Fraunfelder FT Ophthalmology; 2009 Sep; 116(9):1814-7. PubMed ID: 19643481 [TBL] [Abstract][Full Text] [Related]
11. Fluoroquinolone-associated anaphylaxis in spontaneous adverse drug reaction reports in Germany: differences in reporting rates between individual fluoroquinolones and occurrence after first-ever use. Sachs B; Riegel S; Seebeck J; Beier R; Schichler D; Barger A; Merk HF; Erdmann S Drug Saf; 2006; 29(11):1087-100. PubMed ID: 17061914 [TBL] [Abstract][Full Text] [Related]
12. Characterization of Immune Checkpoint Inhibitor-Induced Myasthenia Gravis Using the US Food and Drug Administration Adverse Event Reporting System. Niimura T; Zamami Y; Miyata K; Mikami T; Asada M; Fukushima K; Yoshino M; Mitsuboshi S; Okada N; Hamano H; Sakurada T; Matsuoka-Ando R; Aizawa F; Yagi K; Goda M; Chuma M; Koyama T; Izawa-Ishizawa Y; Yanagawa H; Fujino H; Yamanishi Y; Ishizawa K J Clin Pharmacol; 2023 Apr; 63(4):473-479. PubMed ID: 36453166 [TBL] [Abstract][Full Text] [Related]
13. Assessing fluoroquinolone-associated aortic aneurysm and dissection: Data mining of the public version of the FDA adverse event reporting system. Meng L; Huang J; Jia Y; Huang H; Qiu F; Sun S Int J Clin Pract; 2019 May; 73(5):e13331. PubMed ID: 30809871 [TBL] [Abstract][Full Text] [Related]
14. [Exacerbation of pseudoparalytic myasthenia gravis following azithromycin (Zithromax)]. Cadisch R; Streit E; Hartmann K Schweiz Med Wochenschr; 1996 Feb; 126(8):308-10. PubMed ID: 8701248 [TBL] [Abstract][Full Text] [Related]
15. Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies. Gavin JR; Kubin R; Choudhri S; Kubitza D; Himmel H; Gross R; Meyer JM Drug Saf; 2004; 27(9):671-86. PubMed ID: 15230648 [TBL] [Abstract][Full Text] [Related]
18. Quantitative comparison of the convulsive activity of combinations of twelve fluoroquinolones with five nonsteroidal antiinflammatory agents. Kim J; Ohtani H; Tsujimoto M; Sawada Y Drug Metab Pharmacokinet; 2009; 24(2):167-74. PubMed ID: 19430173 [TBL] [Abstract][Full Text] [Related]
19. Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three italian regions. Leone R; Venegoni M; Motola D; Moretti U; Piazzetta V; Cocci A; Resi D; Mozzo F; Velo G; Burzilleri L; Montanaro N; Conforti A Drug Saf; 2003; 26(2):109-20. PubMed ID: 12534327 [TBL] [Abstract][Full Text] [Related]
20. Safety profile of the fluoroquinolones: analysis of adverse drug reactions in relation to prescription data using four regional pharmacovigilance databases in Italy. Lapi F; Tuccori M; Motola D; Pugi A; Vietri M; Montanaro N; Vaccheri A; Leoni O; Cocci A; Leone R; Conforti A; Moretti U; Sessa E; Mazzaglia G; Mugelli A; Mazzei T; Vannacci A Drug Saf; 2010 Sep; 33(9):789-99. PubMed ID: 20701411 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]